Epcoritamab SC With Rituximab plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma, Including Patients With POD24: Updated Results From EPCORE NHL-2

被引：0

作者：

Merryman, Reid W. ^{[1
]}

Belada, David ^{[2
,3
]}

Sureda, Anna ^{[4
]}

Leppa, Sirpa ^{[5
,6
]}

Vermaat, Joost S. P. ^{[7
]}

Holte, Harald ^{[8
,9
]}

Hutchings, Martin ^{[10
]}

Lugtenburg, Pieternella ^{[11
]}

de Vos, Sven ^{[12
]}

Abrisqueta, Pau ^{[13
]}

Nijland, Marcel ^{[14
,15
]}

Christensen, Jacob Haaber ^{[16
]}

Wahlin, Bjorn E. ^{[17
]}

Linton, Kim M. ^{[18
,19
]}

Wang Liwei ^{[20
]}

Abbas, Aqeel ^{[20
]}

Rana, Ali ^{[20
]}

Quadri, Syed ^{[21
]}

Falchi, Lorenzo ^{[22
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Univ Hosp, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[3] Fac Med, Hradec Kralove, Czech Republic

[4] Univ Barcelona, IDIBELL, Inst Catala Oncol, Hosp Duran i Reynals, Barcelona, Spain

[5] Univ Helsinki, Helsinki, Finland

[6] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland

[7] Leiden Univ, Med Ctr, Leiden, Netherlands

[8] Oslo Univ Hosp, Oslo, Norway

[9] KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[10] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[11] Erasmus MC Canc Inst, Univ Med Ctr, Dept Hematol, Lunenburg Lymphoma Phase Consortium HOVON LLPC 1, Rotterdam, Netherlands

[12] Ronald Reagan Univ Calif Los Angeles Med Ctr, Los Angeles, CA USA

[13] Hosp Univ Vall dHebron, Barcelona, Spain

[14] Univ Med Ctr Groningen, Groningen, Netherlands

[15] Univ Groningen, Groningen, Netherlands

[16] Odense Univ Hosp, Odense, Denmark

[17] Karolinska Inst, Stockholm, Sweden

[18] Christie NHS Fdn Trust, Manchester, Lancs, England

[19] Manchester Canc Res Ctr, Manchester, Lancs, England

[20] Genmab, Plainsboro, NJ USA

[21] AbbVie, N Chicago, IL USA

[22] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-059

引用

页码：S37 / S38

页数：2

共 50 条

[1] Subcutaneous epcoritamab plus GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2
Brody, Joshua D.
Joergensen, Judit Meszaros
Belada, David
Costello, Regis
Trneny, Marek
Vitolo, Umberto
Lewis, David John
Karimi, Yasmin
Sureda, Anna
Andre, Marc
Wahlin, Bjorn E.
Lugtenburg, Pieternella
Jiang, Yajian
Abbas, Aqeel
Song, Yaou
Risum, Malene
Cordoba, Raul
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Subcutaneous Epcoritamab with Rituximab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
Falchi, Lorenzo
Abrisqueta, Pau
Nijland, Marcel
Leppa, Sirpa
Hutchings, Martin
Holte, Harald
Merryman, Reid W.
Lugtenburg, Pieternella
de Vos, Sven
Cheah, Chan Y.
Christensen, Jacob Haaber
Arcaini, Luca
Drott, Kristina
Hellstrom, Mats
Leslie, Lori A.
Vitolo, Umberto
Rana, Ali
Abbas, Aqeel
Wang, Liwei
Minh Dinh
Belada, David
BLOOD, 2022, 140 : 1464 - 1466
[3] Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5
Mazza, Irit Avivi
Kim, Won Seog
Ko, Shen
Grande, Carlos
Lavie, David
Chism, David
Seliem, Mostafa
Jeng, Edwin E.
Joshi, Neha
Siddani, Satya
Assaily, Wissam
Sacchi, Mariana
Dinh, Minh
Avigdor, Abraham
BLOOD, 2023, 142
[4] Epcoritamab with rituximab plus lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7
Lori, Leslie A.
Falchi, Lorenzo
Vermaat, Joost S. P.
Musuraca, Gerardo
Belada, David
Nijland, Marcel
Christensen, Jacob Haaber
Offner, Fritz
Hoehn, Daniela
Marek, Jennifer
Wang, Liwei
Mei, J. P.
Abrisqueta, Pau
Brody, Joshua D.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] LENALIDOMIDE PLUS RITUXIMAB IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Della Cioppa, P.
Lucania, A.
Esposito, M.
Improta, S.
Mastrullo, L.
HAEMATOLOGICA, 2015, 100 : 151 - 151
[6] Epcoritamab SC plus GemOx Leads to High Complete Metabolic Response Rates in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Stem Cell Transplant: Updated Results from Epcore NHL-2
Brody, Joshua
Joergensen, Judit Meszaros
Belada, David
Costello, Regis T.
Trneny, Marek
Vitolo, Umberto
Lewis, David
Karimi, Yasmin H.
Sureda Balari, Anna Maria
Andre, Marc
Wahlin, Bjorn E.
Lugtenburg, Pieternella
Galderisi, Faith
Abbas, Aqeel
Song, Yaou
Risum, Malene
Cordoba, Raul
BLOOD, 2023, 142
[7] Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update
Lorenzo, Falchi
Sirpa, Leppa
Wahlin, Bjorn E.
Marcel, Nijland
Christensen, Jacob H.
De, Vos Sven
Harald, Holte
Linton, Kim M.
Aqeel, Abbas
Wang Liwei
Minh, Dinh
Brian, Elliott
David, Belada
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S31
[8] Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Linton, Kim M.
Wahlin, Bjorn
Leepa, Sirpa
Morschhauser, Franck
Elliot, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
BLOOD, 2021, 138
[9] LENALIDOMIDE/RITUXIMAB (R2) VERSUS RITUXIMAB/PLACEBO EFFICACY BY POD24 STATUS AND TIME TO NEXT TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL (AUGMENT)
Pinto, A.
Gribben, J.
Trneny, M.
Izutsu, K.
Fowler, N. H.
Hong, X.
Zhang, H.
Offner, F.
Scheliga, A.
Nowakowski, G.
Re, F.
Fogliatto, L. M.
Scheinberg, P.
Flinn, I.
Moreira, C.
Czuczman, M.
Kalambakas, S.
Fustier, P.
Wu, C.
Leonard, J. P.
HAEMATOLOGICA, 2019, 104 : 7 - 8
[10] EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma
Falchi, Lorenzo
Morschhauser, Franck
Linton, Kim
Huang, Huiqiang
Galderisi, Faith
Quadri, Syed
Zeng, Lingmin
Hoehn, Daniela
Seymour, John F.
BLOOD, 2023, 142

← 1 2 3 4 5 →